Ethicon Endo-Surgery buy
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson subsidiary announces definitive agreement to acquire SurgRx for an undisclosed amount Aug. 11. SurgRx' EnSeal vascular sealant complements Ethicon Endo-Surgery's Harmonic ultrasonic device. EnSeal is suitable for larger vessels while Harmonic is appropriate for "fine tuning" in surgery, Ethicon Endo-Surgery says. The deal "has the potential to expand the global availability of the EnSeal product line," SurgRx Chairman Rodney Perkins stated. EnSeal was 510(k) cleared in 2003
You may also be interested in...
J&J Spotlights AAA Device, Thermocool Extensions During Analyst Meeting
Johnson & Johnson is looking to the Nevo sirolimus-eluting stent and entry into fast-growing endovascular device segments, such as the abdominal aortic aneurysm market, to restore growth in its struggling Cordis unit
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.